Add like
Add dislike
Add to saved papers

Optimal frequency of visits for patients with systemic lupus erythematosus to measure disease activity over time.

OBJECTIVE: adjusted mean Systemic Lupus Erythematosus Disease Activity Index (SLEDAI; AMS) measures lupus disease activity over time. Our aim was to determine optimal visit frequency for calculating AMS.

METHODS: patients followed monthly for 12 consecutive visits were included. AMS was calculated using all of the SLEDAI 2000 (AMS(GOLD) using all 12 visits), only quarterly visits (AMS(3), using visits 3 months apart), semiannual visits (AMS(6), using first, middle, and last visits only), and annual visits (AMS(12), using only the first and last visits). Comparisons of AMS(3), AMS(6), and AMS(12) with AMS(GOLD) are made using descriptive statistics.

RESULTS: seventy-eight patients were included (92% women, mean age at SLE diagnosis 30.1 yrs and at study start 46.2 yrs). The mean (SD) AMS(GOLD) for the entire year was 2.05 (1.66), for AMS(3) 1.99 (1.65), for AMS(6) 2.12 (1.87), and for AMS(12) 2.08 (1.83). Mean (SD) of the absolute differences with AMS(GOLD): for AMS(3) 0.29 (0.33), for AMS(6) 0.45 (0.59), and for AMS(12) 0.61 (0.58). Differences that were < 0.5 were considered minimal while those ≥ 1 were deemed important. Comparing AMS(GOLD) to AMS(3), 82% of the differences were minimal and 3% were important. When comparing to AMS(6), 68% were minimal and 10% were important, while comparing to AMS(12), 50% were minimal and 21% were important.

CONCLUSION: usual clinic visits occurring quarterly offer a good estimation of disease activity over a 1-year period and are preferred over semiannual and annual visits.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app